GSK has reported a total operating profit of £1.94bn in the third quarter (Q3) of 2023, a 64% increase from the £1.19bn earned during the same quarter of the previous year.
The company’s total turnover stood at £8.14bn, up 4% from £7.8bn in the same period in 2022.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
During the first nine months of 2023, the company generated £22.2bn turnover, an increase from £21.9bn in the same period of the previous year.
For Q3, it achieved a 34% adjusted operating margin with an adjusted earning per share (EPS) of 50.4p.
In the first nine months of 2023, it generated an operating profit of £6.1bn, compared to £4.5bn in the previous year.
GSK is expecting a turnover increase between 12% and 13% for the full year, and an adjusted operating profit increase between 13% and 15%.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company anticipates adjusted EPS growth between 17% and 20% for the full year.
GSK CEO Emma Walmsley stated: “Competitive performance was broadly based but benefitted particularly from the outstanding US launch of Arexvy, the world’s first RSV vaccine.
“Our excellent execution supports an upgrade to our full-year 2023 guidance and we have clear momentum as we look ahead to deliver our 2026 outlooks.
“GSK’s longer-term outlook also continues to strengthen, with progress in our vaccines pipeline, the development of our ultra long-acting HIV portfolio and significant new prospects in respiratory.”
